Bragging rights over whose drug shifts the most weight continued at the European Association for the Study of Diabetes (EASD) ...
Continuing this year’s trend in upward deal values, Novartis AG is paying Abogen Biosciences $575 million up front, with a potential $7.2 billion in milestones, picking up exclusive worldwide rights ...
With positive data in fibrostenotic Crohn’s disease (FSCD) from the open-label extension part of the phase IIa Stenova in hand, Agomab Therapeutics NV is looking forward to the next stage of clinical ...
Edwards Lifesciences Corp. won U.S. FDA approval of an expandable surgical pulmonary valve for kids that held breakthrough device designation.
Australia is making its most ambitious attempt in decades to turn clinical research into a pillar of economic growth, rolling out a national one-stop shop aimed at cutting red tape and making the ...
Qbiotics Group Ltd. is seeking up to AU$40 million (US$27.76 million) to advance its intratumoral oncology pipeline to proof of concept and position the programs for partnering, following phase II ...
August 2026 brought 93 clinical trial updates tracked by BioWorld, with late-stage programs accounting for the largest share of activity. Phase III generated 41 readouts during the month, compared ...
CD-228V, a phase I antibody-drug conjugate (ADC) licensed from Pfizer Inc. for $12 million up front and more than $1 billion ...
The incidence of both MTAP deletion and RAS mutations in pancreatic cancer is about 30%-40%, so inhibiting both pathways could be a promising approach to treatment, but it remains unclear whether ...
With age, muscle loses mitochondrial function and abundance, as these organelles progressively accumulate damage and become less efficient. However, the proportion of oxidative muscle fibers, which ...
Researchers from Shandong First Medical University and Shandong Academy of Medical Sciences used structure-based virtual screening to identify XJ2-2, an epidermal growth factor receptor (EGFR) ...
Hangzhou Healthytide Biotechnology Co. Ltd. has reported new conjugates comprising a polypeptide targeting urokinase plasminogen activator surface receptor (uPAR) covalently linked to a radionuclide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results